Literature DB >> 23669337

Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets.

Changbo Ou1, Deyu Tian, Yong Ling, Qing Pan, Qing He, Francis O Eko, Cheng He.   

Abstract

Chlamydia abortus (C. abortus) is an obligate intracellular pathogen that causes abortion in pigs and poses a zoonotic risk in pregnant women. Although attenuated and inactivated vaccines are available, they do not provide complete protection in animals underlining the need to develop new vaccines. In this study, we tested the hypothesis that intramuscular immunization with an ompA-based phage-mediated DNA chlamydial vaccine candidate will induce significant antigen-specific cellular and humoral immune responses. Thus, groups of piglets (five per group) were immunized intramuscularly with the phage-MOMP vaccine (λ-MOMP) or a commercial live-attenuated vaccine (1B vaccine) or a GFP-expressing phage (λ-GFP) or phosphate buffered saline (PBS) (control) and antigen-specific cell-mediated and humoral immune responses were evaluated. By day 63 post-immunization, the λ-MOMP vaccine elicited significantly higher (P<0.05) levels of antigen-specific serum IgG antibody responses than the 1B vaccine or control did. Also, piglets immunized with λ-MOMP vaccine had significantly higher (P<0.05) MOMP-specific lymphocyte proliferative responses compared to those immunized with the 1B vaccine or control. Furthermore, the total T-cell numbers (CD3+) and the proportion of CD4+ and CD8+ T-cell subsets as well as the ratio of CD4+/CD8+ T cells elicited following immunization were comparable between the λ-MOMP- and 1B-vaccinated animals on both days 63 and 70. Interestingly, although the proportion of CD3+CD4-CD8- double negative T cells on day 63 was significantly higher (P<0.05) in the 1B vaccine group compared to the λ-MOMP-immunized group, there was a significant decrease in the proportion of this T-cell population on day 70 in the 1B compared to the λ-MOMP vaccinated group. These results indicate that the λ-MOMP DNA vaccine is capable of inducing antigen-specific cellular and humoral immune responses that may provide protective immunity against a live challenge infection with C. abortus.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23669337     DOI: 10.1016/j.intimp.2013.04.027

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

Review 1.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

2.  A Novel Molecular Design for a Hybrid Phage-DNA Construct Against DKK1.

Authors:  Saeed Khalili; Mohamad Javad Rasaee; Taravat Bamdad; Maysam Mard-Soltani; Majid Asadi Ghalehni; Abolfazl Jahangiri; Mohammad Hassan Pouriayevali; Mohammad Reza Aghasadeghi; Fatemeh Malaei
Journal:  Mol Biotechnol       Date:  2018-11       Impact factor: 2.695

3.  Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge.

Authors:  Zonghui Zuo; Yongjuan Zou; Qiang Li; Yongxia Guo; Tianyuan Zhang; Jie Wu; Cheng He; Francis O Eko
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

4.  Construction of Recombinant HVT Expressing PmpD, and Immunological Evaluation against Chlamydia psittaci and Marek's Disease Virus.

Authors:  Shanshan Liu; Wei Sun; Jun Chu; Xiufen Huang; Zongxue Wu; Minxin Yan; Qiang Zhang; Peng Zhao; Joseph U Igietseme; Carolyn M Black; Cheng He; Yongqing Li
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

Review 5.  Bacteriophages and Their Immunological Applications against Infectious Threats.

Authors:  Elena Criscuolo; Sara Spadini; Jacopo Lamanna; Mattia Ferro; Roberto Burioni
Journal:  J Immunol Res       Date:  2017-04-16       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.